Though many drugs have been shown to have activity in brain metastases, none are commonly used. Accordingly, pharmaceutical management of brain metastases is an area with great unmet need and little competition. This Market Brief examines the epidemiology, diagnosis and treatment of brain metatases, highlights unmet needs in treatment, and provides an examination of drugs in the pipeline and as well as drugs currently indicated for other cancer types.
